Existing ocular drug delivery systems are fairly primitive and inefficient, but the stage is set
for the rational design of newer and significantly improved systems. The focus of this review …

Glaucoma is a chronic, progressive disease in which retinal ganglion cells disappear and
subsequent, gradual reductions in the visual field ensues. Glaucoma eye drops have …

Written by experts in the field, this comprehensive resource offers valuable information on
the practical uses of drugs in primary eye care. Discussions of the pharmacology of ocular …

For some time the medical treatment of glaucoma has consisted of topical β-blockers,
adrenergic agents, miotics and oral carbonic anhydrase inhibitors (CAIs). However, the …

Glaucoma is the leading cause of irreversible blindness in the world. It is estimated that by
the year 2000, 66.8 million people will be affected, of whom 6.7 million will be blind in both …

Glaucoma represents a major cause of vision loss throughout the world. Primary open-angle
glaucoma, the most common form of glaucoma, is a chronic, progressive disease often …

Background β-Blockers are avoided in asthma over concerns regarding acute
bronchoconstriction. Risk is greatest following acute exposure, including the potential for …

Topical β-blockers reduce the intraocular pressure (IOP) by blockade of sympathetic nerve
endings in the ciliary epithelium causing a fall in aqueous humour production. Two types of …

Medications used to treat glaucoma can have clinically important systemic effects in some
patients; these effects may not be recognized in elderly patients who have chronic medical …

OBJECTIVE: To compare the safety and intraocular pressure (IOP)-lowering efficacy of once-
daily travoprost (0.0015% and 0.004%) to twice-daily timolol 0.5%. DESIGN: Prospective, 6 …